A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Summary

This is a multicenter, parallel multicohort, phase 2, single-arm study for adjunctive treatment in participants with high-risk myeloid malignancies undergoing allogeneic HSCT. The purpose of this study is to assess the safety and preliminary efficacy of off-the-shelf (OTS) ex vivo expanded NK cells (SAR445419) in improving relapse free survival (RFS).

Timeline

Start

2024-10-08

Primary completion

2027-02-12

Completion

2027-10-11

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision to cancel trial, not related to safety concern.”

Drugs

Indications